Aadi axes 80% of staff after registrational Phase II trial fails

Aadi axes 80% of staff after registrational Phase II trial fails

Submitted by admin on August 21, 2024 - 11:36am
Source: 
Clinical Trials Arena
News Tags: 
Aadi Biosciences
clinical trials
layoffs
mTOR inhibitors
nab-sirolimus
Headline: 
Aadi axes 80% of staff after registrational Phase II trial fails
snippet: 

Aadi Biosciences has instituted cash-saving measures after the company decided to halt the registrational Phase II PRECISION1 trial for its mTOR inhibitor, nab-sirolimus.

Do Not Allow Advertisers to Use My Personal information